Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHIQDC)

• Drug Name: CUDC-907 Drug Info
• Synonyms: CUDC-907; 1339928-25-4; Fimepinostat; CUDC 907; UNII-3S9RX35S5X; CUDC907; 3S9RX35S5X; CHEMBL3622533; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; Fimepinostat [USAN]; PI3K/HDAC Inhibitor centn; MLS006010994; SCHEMBL1284705; GTPL8952; KS-00000TDO; EX-A742; AOB6775; DTXSID90712307; MolPort-023-293-550; JOWXJLIFIIOYMS-UHFFFAOYSA-N; HMS3656H04; BCP06870; s2759; BDBM50188961; 2341AH; ZINC73488511; ABP001045; AKOS026750340; SB16569; CUDC-907 (PI3K/HDAC Inhibi

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 1/2	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1	[2]
Neuroblastoma	2D11.2	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 54575456
  CAS Number: CAS 1339928-25-4
  TTD Drug ID: DMHIQDC

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[5]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[6]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[3]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[8]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[9]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[3]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[11]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[12]

Drug(s) Targeting PI3-kinase gamma (PIK3CG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[13]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[14]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[15]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[3]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[16]
GDC-0032	DMT4QHD	Breast cancer	2C60-2C65	Phase 3	[3]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[17]
SAR245409	DMQM7IL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[18]
XL147	DMML7BE	Solid tumour/cancer	2A00-2F9Z	Phase 2	[18]
SF1126	DML10K3	Head and neck cancer	2D42	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[3]
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Modulator	[4]

References

• [1] ClinicalTrials.gov (NCT04278768) Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Curis.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res.2012 Aug 1;18(15):4104-13.
• [5] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [6] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [9] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [10] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [11] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
• [14] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [15] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [16] Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
• [19] An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.